- Home
- VMD vs CRDF Comparison
VMD vs CRDF Comparison
Compare VMD & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMD | CRDF |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 142.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VMD | CRDF |
|---|---|---|
| Price | $7.23 | $3.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 147.5K | ★ 1.1M |
| Earning Date | 11-05-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.92 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $254,794,000.00 | $501,000.00 |
| Revenue This Year | $20.05 | N/A |
| Revenue Next Year | $17.44 | N/A |
| P/E Ratio | $21.41 | ★ N/A |
| Revenue Growth | ★ 18.89 | N/A |
| 52 Week Low | $5.93 | $1.90 |
| 52 Week High | $8.62 | $4.99 |
Technical Indicators
Market Signals| Indicator | VMD | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 52.05 | 67.49 |
| Support Level | $7.13 | $2.61 |
| Resistance Level | $7.62 | $3.31 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 17.43 | 85.63 |
Price Performance
Historical ComparisonAbout VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.